

28 Aug 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Roche's TIGIT data leak; Regeneron gets important US approvals; COVID subvariant vaccine progress; Pfizer's RSV vaccine extended approval; and Japan recommends lecanemab for Alzheimer's.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 25 August 2023, including: [Roche Holding AG's](#) TIGIT data leak; [Regeneron Pharmaceuticals, Inc.](#) gets important US approvals; COVID subvariant vaccine progress; [Pfizer Inc.](#)'s RSV vaccine extended approval; and Japan recommends lecanemab for Alzheimer's.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Roche's Data Leak Reawakens Hopes For TIGIT Lung Cancer Drug](#)" - Scrip, 23 Aug, 2023.)

(Also see "[UPDATED: Regeneron Wins Same-Day Veopoz, High-Dose Eylea US FDA Approvals](#)" - Scrip, 18 Aug, 2023.)

(Also see "[Drug Makers Gear Up For 2023-2024 COVID-19 Season With Subvariant Vaccines](#)" - Scrip, 22 Aug, 2023.)

(Also see "[Pfizer's Abrysvo Is First Maternal Vaccine For RSV To Protect Infants](#)" - Scrip, 21 Aug, 2023.)

(Also see "[Japan Committee Recommends Lecanemab Approval](#)" - Scrip, 22 Aug, 2023.)

[Click here to explore this interactive content online](#) 